Physician profile
Keith A Wright
NPI 1174562227
$3,991.53
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $509 · 2020: $715 · 2021: $904 · 2022: $732 · 2023: $1,004 · 2024: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,131.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $653.32 | 2019-2024 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $446.98 | 2019-2024 | |
| Amgen INC. | $406.85 | 2019-2023 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $362.41 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $206.02 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $204.47 | 2019-2023 | Breztri |
| Amarin Pharma, INC. | $199.13 | 2020-2022 | |
| Allergan, INC. | $198.17 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.42 | 2019-2023 | Synjardy, Jardiance, Tradjenta |
| Lilly USA, LLC | $169.10 | 2020-2023 | Mounjaro, Trulicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.51 | 2019-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $111.39 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $84.49 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $78.15 | 2019-2022 | |
| Astellas Pharma US INC | $65.44 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $64.39 | 2019-2022 | |
| Eisai INC. | $58.50 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $53.87 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $40.59 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $38.95 | 2020-2022 | |
| Radius Health, INC. | $35.33 | 2019-2022 | |
| Grifols USA, LLC | $31.77 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $23.70 | 2021 | |
| Abbott Laboratories | $19.55 | 2021 | |
| Dexcom, INC. | $18.26 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.84 | 2019 | |
| Esperion Therapeutics, INC. | $16.31 | 2021 | |
| Neos Therapeutics, Lp | $14.91 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.67 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $12.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.